Repare Therapeutics And Debiopharm Have Dosed The First Patient In Phase 1/1b MYTHIC Trial Investigating Lunresertib In Combination With Debio 0123

Repare Therapeutics And Debiopharm Have Dosed The First Patient In Phase 1/1b MYTHIC Trial Investigating Lunresertib In Combination With Debio 0123

BenzingaApr 30 19:11

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

Debiopharm (), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, and Repare Therapeutics Inc. ("Repare")

BusinesswireApr 30 19:05

Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 32% Plummet

Unfortunately for some shareholders, the Repare Therapeutics Inc. (NASDAQ:RPTX) share price has dived 32% in the last thirty days, prolonging recent pain. The recent drop completes a disastrous twe

Simply Wall StApr 28 21:43

Repare Therapeutics Announces Board Changes and FD Disclosure

TipRanksApr 27 04:36

Repare Therapeutics Names Steven H. Stein to Board

Repare Therapeutics Names Steven H. Stein to Board

Dow JonesApr 27 04:05

Buy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Outlook and Attractive Valuation

TipRanksApr 21 21:35